Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Search
Innovation in medicinal chemistry
Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
Facts About Asthma
Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.
Better Access to Healthcare for Indigenous Peoples
Indigenous Peoples often experience poor access to health care. Our initiatives from Canada and New Zealand aim to overcome the gap.
Collaboration with Mary Tyler Moore Vision Initiative
Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
Results for Jardiance EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results